Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM)

NCT06686524 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Dermatomyositis, Juvenile
Dermatomyositis

Interventions

DRUG: Anti-CD19 UCAR-T cells

Sponsor

Chongqing Precision Biotech Co., Ltd